脑部放疗，上午比下午敏感许多！
2 V* A: n4 Q& t" P& E. r* r) x$ v1 R/ d5 C6 ^8 i; C
: V$ l! V, T. l& i1 J
Cancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.% c3 B2 h7 o( ^/ `
Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?1 T8 A$ ?& [) f/ v* {# a) }0 U
Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.3 Q1 F4 j. d* L7 z K) N+ t
SourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.# G$ V* D, ?% J$ z# {1 }' p% {
* T3 d; d" t& g. c! W% K
Abstract
% V' y* Q5 e6 z. S! e7 D9 eBACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.
4 L# r" ~1 u* e7 j+ d' |5 U) u4 E; ^- c% Q2 Z1 U7 o, O
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.
) K4 O# A, A/ Y
; x3 g; y$ |+ B% n( nRESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).
- [) ^& I' R9 W8 }1 E+ w% k5 ]2 O2 ?
CONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.! T/ Y. w: c. \8 Q1 Z
2 n+ j) T8 ]* y |
“砰”！国产新药获批，击穿肺癌靶向
作者：Tony
与欧美人种不同的是，亚洲肺癌患者EGFR突变率高，约达到50%[1]，有更多机
父亲生病一周年小记
2024年3月9日父亲感觉吸气的时候胸部有压迫感去卫生院做了个CT，CT还要经上级医院审
母亲奥西耐药后应如何选择
2022年10月确诊肺腺癌，基因检测结果EGFR21，服用奥希替尼。2024年6月CT影像检查缓慢
又一个肺癌四代靶向药倒下，奥希替尼
作者：闵
自第一款EGFR-TKI易瑞沙（即吉非替尼）于2005年在我国上市以来，EGFR-TKI药
求助求助：妈妈的基因检测结果，EGFR
请版主帮忙@一下大神们，帮忙出一下注意。
帖子更新到2025年3月7日，首次手术样本，送
0 ~' w/ q4 }( [4 O
显身卡
